Product Description: Selicrelumab is an agonist CD40 antibody, induces changes in the tumor microenvironment. Selicrelumab can be used for the research of pancreatic cance and neoadjuvant study[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Katelyn T Byrne, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Clin Cancer Res. 2021 Aug 15;27(16):4574-4586.
CAS Number: 1622140-49-1
Molecular Weight: N/A
Compound Purity: 97.64
Research Area: Cancer
Solubility: H2O
Target: Others